Cyclosporine Modified (cyclosporine, modified)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Cyclosporine is a cyclosporin immunosuppressive agent and disease-modifying antirheumatic drug.
Cyclosporine is used for the prevention of rejection of kidney, liver, or heart allografts. The manufacturers and some clinicians recommend that cyclosporine be used in conjunction with corticosteroid therapy, at least initially. Cyclosporine is also used for the treatment of chronic allograft rejection in patients previously treated with other immunosuppressive agents (e.g., azathioprine).
Generic name: cyclosporine, modified
Pronunciation: (SYE-kloe-SPOR-in MY-crow-ee-MULL-shun)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Cyclosporine Modified
Indications
The following indications are listed for Cyclosporine Modified:
- Prevention Of Cardiac Transplant Rejection
- Prevention Of Kidney Transplant Rejection
- Prevention Of Liver Transplant Rejection
- Rheumatoid Arthritis
- Severe Recalcitrant Psoriasis
Also known as: Arthritis Deformans, Arthrosis Deformans, Cardiac Transplant Rejection Prophylaxis, Heart Transplant Rejection Prophylaxis, Hepatic Transplant Rejection Prophylaxis, Kidney Transplant Rejection Prophylaxis, Liver Transplant Rejection Prophylaxis, Nodose Rheumatism, Renal Transplant Rejection Prophylaxis, Rheumatic Arthritis, Rheumatic Gout, Severe Intractable Psoriasis, Severe Refractory Psoriasis.
Dosing
No dosing information is available for this tab.
Cyclosporine is administered orally as conventional (nonmodified) or modified formulations; the drug also is administered by IV infusion.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Although there are no adequate and well-controlled studies using cyclosporine in pregnant women, the drug has been shown to be embryotoxic and fetotoxic in rats and rabbits when administered orally at maternally toxic doses. Fetal toxicity was observed in these animals at doses 0.8-5.4 times (corrected for body surface area) the human maintenance dose of 6 mg/kg. Cyclosporine caused increased prenatal and postnatal mortality and reduced fetal weight with related skeletal retardation in these rats and rabbits. In women who received cyclosporine therapy throughout pregnancy, premature birth (gestational age of 28-36 weeks) and reduced neonatal weight occurred consistently. Most of the pregnancies also were complicated by growth retardation (which may be severe), fetal loss, preeclampsia, eclampsia, premature labor, abruptio placentae, oligohydramnios, Rh incompatibility, and fetoplacental dysfunction. Premature birth was the most frequent complication, while being small for gestational age and neonatal complications were less common. Malformations occurred in some neonates and in a few cases of fetal loss. A full-term neonate was born to a woman who underwent a renal transplant prior to conception and received 450 mg of cyclosporine alone daily throughout pregnancy, and other successful pregnancies have been reported in allograft recipients who received the drug daily during pregnancy. Abnormalities in renal function or blood pressure were not observed in a limited number of children 7 years of age or younger exposed to cyclosporine in utero.
Cyclosporine should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. In patients with psoriasis, the risks and benefits of therapy with cyclosporine during pregnancy should be evaluated carefully, with discontinuance of therapy considered seriously because of possible disruption of the interaction between the mother and fetus.
Since cyclosporine is distributed into milk, nursing should be avoided in women receiving the drug.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.